RPTX (Repare Therapeutics) Forward Dividend Yield % : 0.00% (As of Jan. 19, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics Forward Dividend Yield %?

As of today (2025-01-19), the Forward Annual Dividend Yield of Repare Therapeutics is 0.00%.

As of today (2025-01-19), the Trailing Annual Dividend Yield of Repare Therapeutics is 0.00%.

RPTX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.58
* Ranked among companies with meaningful Forward Dividend Yield % only.

Repare Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Repare Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Repare Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repare Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Forward Dividend Yield % falls into.

Repare Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Repare Therapeutics (NAS:RPTX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Repare Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Repare Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1

Website

https://www.reparerx.com

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.

Executives

Maria Koehler	officer: EVP, Chief Medical Officer	C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Michael Zinda	officer: EVP, Chief Science Officer	C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Steve Forte	officer: EVP, Chief Financial Officer	C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Lloyd Mitchell Segal	officer: President and CEO	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Susan Molineaux	director	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage I, L.p.	10 percent owner	ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures V, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104